(firstQuint)Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia.

 This was an open-label study of 60 weeks duration in elderly patients (65 years) with primary hypercholesterolemia or combined dyslipidemia who completed the 12 week treatment in study NK-104-306 and who met the inclusion/exclusion criteria.

 Patients who qualified started open-label treatment with pitavastatin 2 mg QD.

 The dose of pitavastatin could be increased to 4 mg QD after at least 8 weeks of treatment at 2 mg QD, in patients who failed to attain their LDL-C target.

.

 Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia@highlight

This is an open-label extension study of NK-104-306 (NCT00257686) for elderly patients with hypercholesterolemia or combined dyslipidemia.

